168 related articles for article (PubMed ID: 26845928)
1. [Predictive factors of response to Direct Acting Antivirals therapy Drug resistance hepatitis C virus].
Suda G; Yamasaki K; Sakamoto N
Nihon Rinsho; 2015 Dec; 73 Suppl 9():189-92. PubMed ID: 26845928
[No Abstract] [Full Text] [Related]
2. Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals?
Feld JJ
Gastroenterology; 2012 May; 142(6):1356-9. PubMed ID: 22537443
[No Abstract] [Full Text] [Related]
3. Clinical relevance of HCV antiviral drug resistance.
Welsch C; Zeuzem S
Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
Li Z; Chen ZW; Ren H; Hu P
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
[TBL] [Abstract][Full Text] [Related]
5. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
Wyles DL; Gutierrez JA
J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
[TBL] [Abstract][Full Text] [Related]
6. [Hepatitis C therapy: a problem almost solved].
Rizzetto M
Recenti Prog Med; 2014 Jun; 105(6):225-6. PubMed ID: 25002283
[TBL] [Abstract][Full Text] [Related]
7. Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.
Welsch C
Drug Discov Today Technol; 2014 Mar; 11():19-25. PubMed ID: 24847649
[TBL] [Abstract][Full Text] [Related]
8. Advances in and the future of treatments for hepatitis C.
Cheng R; Tu T; Shackel N; McCaughan GW
Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):633-47. PubMed ID: 24846594
[TBL] [Abstract][Full Text] [Related]
9. [Development status of DAA against hepatitis C].
Kato N; Nakagawa R; Goto K; Muroyama R; Matsubara Y
Nihon Rinsho; 2015 Dec; 73 Suppl 9():262-8. PubMed ID: 26845942
[No Abstract] [Full Text] [Related]
10. SHARED: An International Collaboration to Unravel Hepatitis C Resistance.
Howe AYM; Ceccherini-Silberstein F; Dietz J; Popping S; Grebely J; Rodrigo C; Lennerstrand J; Douglas MW; Parczewsk M; Harrigan PR; Pawlotsky JM; Garcia F; Collaborators S
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452444
[TBL] [Abstract][Full Text] [Related]
11. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
Vachon ML; Dieterich DT
Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
[TBL] [Abstract][Full Text] [Related]
12. Impact of new hepatitis C treatments in different regions of the world.
Wei L; Lok AS
Gastroenterology; 2014 May; 146(5):1145-50.e1-4. PubMed ID: 24662488
[No Abstract] [Full Text] [Related]
13. New hepatitis C therapies: the toolbox, strategies, and challenges.
Pawlotsky JM
Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
[TBL] [Abstract][Full Text] [Related]
14. HCV drug resistance and DAA agents.
Szymanek A; Krzysztof S
Przegl Epidemiol; 2013; 67(3):403-6, 513-5. PubMed ID: 24340550
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of interferon resistance in hepatitis C.
Gretch D
Lancet; 2001 Nov; 358(9294):1662-4. PubMed ID: 11728538
[No Abstract] [Full Text] [Related]
16. Treating hepatitis B virus/hepatitis C virus coinfected patients with direct-acting hepatitis C virus antivirals only is not safe.
Ozaras R; Sunbul M; Parlak M; Bodur H; Leblebicioglu H
Hepatology; 2016 Nov; 64(5):1825-1827. PubMed ID: 27043022
[No Abstract] [Full Text] [Related]
17. [How to treat non-responders to antiviral bitherapy for hepatitis C?].
Guyader D
Gastroenterol Clin Biol; 2007 Mar; 31(3):317-24. PubMed ID: 17396096
[No Abstract] [Full Text] [Related]
18. Efficacy of Direct-Acting Antivirals Compared with Older Agents for Hepatitis C.
Ta K; Zehtabchi S
Am Fam Physician; 2017 Jun; 95(11):Online. PubMed ID: 28671433
[No Abstract] [Full Text] [Related]
19. Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E
Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
[TBL] [Abstract][Full Text] [Related]
20. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
Pár A
Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
